IT1264490B - Antigene 90k associato a tumori. - Google Patents

Antigene 90k associato a tumori.

Info

Publication number
IT1264490B
IT1264490B ITRM920099A ITRM920099A IT1264490B IT 1264490 B IT1264490 B IT 1264490B IT RM920099 A ITRM920099 A IT RM920099A IT RM920099 A ITRM920099 A IT RM920099A IT 1264490 B IT1264490 B IT 1264490B
Authority
IT
Italy
Prior art keywords
antigen
molecular weight
cancer patient
cancer
antigen associated
Prior art date
Application number
ITRM920099A
Other languages
English (en)
Inventor
Stefano Iacobelli
Clara Natoli
Original Assignee
Uni Degli Studi G D Annunzio C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi G D Annunzio C filed Critical Uni Degli Studi G D Annunzio C
Publication of ITRM920099A0 publication Critical patent/ITRM920099A0/it
Priority to ITRM920099A priority Critical patent/IT1264490B/it
Priority to AU36290/93A priority patent/AU3629093A/en
Priority to IL104745A priority patent/IL104745A0/xx
Priority to PCT/EP1993/000379 priority patent/WO1993017119A2/en
Priority to CN93101808A priority patent/CN1076629A/zh
Priority to AU34979/93A priority patent/AU3497993A/en
Priority to PCT/EP1993/000385 priority patent/WO1993016181A1/en
Priority to ZA931100A priority patent/ZA931100B/xx
Publication of ITRM920099A1 publication Critical patent/ITRM920099A1/it
Application granted granted Critical
Publication of IT1264490B publication Critical patent/IT1264490B/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Viene fornito un antigene associato a tumori sostanzialmente purificato proveniente dal fluido di coltura di cellule di mammella umana, CG-5, di siero di paziente affetta da cancro della mammella, e di fluido ascitico di paziente affetta da cancro alle ovaie. L'antigene nativo che ha un peso molecolare di circa 90.000 dalton è presente come un complesso di elevato peso molecolare. La purificazione e la caratterizzazione dell'antigene sono fornite come pure le sequenze nucleotidiche che codificano per l'antigene 90K.
ITRM920099A 1992-02-17 1992-02-17 Antigene 90k associato a tumori. IT1264490B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ITRM920099A IT1264490B (it) 1992-02-17 1992-02-17 Antigene 90k associato a tumori.
AU36290/93A AU3629093A (en) 1992-02-17 1993-02-16 A 90K tumor-associated antigen, IR-95
IL104745A IL104745A0 (en) 1992-02-17 1993-02-16 90k tumor-associated antigen,method for the preparation thereof and pharmaceutical compositions containing the same
PCT/EP1993/000379 WO1993017119A2 (en) 1992-02-17 1993-02-16 A 90k tumor-associated antigen, ir-95
CN93101808A CN1076629A (zh) 1992-02-17 1993-02-17 90k肿瘤相关抗原ir-95的遗传序列
AU34979/93A AU3497993A (en) 1992-02-17 1993-02-17 A 90K tumor-associated antigen, IR-95
PCT/EP1993/000385 WO1993016181A1 (en) 1992-02-17 1993-02-17 A 90k tumor-associated antigen, ir-95
ZA931100A ZA931100B (en) 1992-02-17 1993-02-17 A 90K tumor-associated antigen, IR-95.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920099A IT1264490B (it) 1992-02-17 1992-02-17 Antigene 90k associato a tumori.

Publications (3)

Publication Number Publication Date
ITRM920099A0 ITRM920099A0 (it) 1992-02-17
ITRM920099A1 ITRM920099A1 (it) 1993-08-18
IT1264490B true IT1264490B (it) 1996-09-24

Family

ID=11400690

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920099A IT1264490B (it) 1992-02-17 1992-02-17 Antigene 90k associato a tumori.

Country Status (6)

Country Link
CN (1) CN1076629A (it)
AU (2) AU3629093A (it)
IL (1) IL104745A0 (it)
IT (1) IT1264490B (it)
WO (2) WO1993017119A2 (it)
ZA (1) ZA931100B (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012681A1 (en) * 1993-11-05 1995-05-11 New York University Methods relating to ir-95
CN1313603C (zh) * 2004-09-30 2007-05-02 北京大学人民医院 抗人卵巢癌单克隆抗体杂交瘤细胞系及其单克隆抗体和应用
GB2435882A (en) * 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76877A (en) * 1984-11-02 1991-11-21 Oncogen Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
IT1239719B (it) * 1990-04-23 1993-11-15 Univ Degli Studi Annunzio Uso dell'anticorpo monoclonale sp-2 nella diagnostica clinica ed il monitoraggio del progredire dell'infezione hiv

Also Published As

Publication number Publication date
WO1993016181A1 (en) 1993-08-19
ZA931100B (en) 1994-08-17
IL104745A0 (en) 1993-06-10
AU3629093A (en) 1993-09-13
CN1076629A (zh) 1993-09-29
AU3497993A (en) 1993-09-03
ITRM920099A1 (it) 1993-08-18
WO1993017119A2 (en) 1993-09-02
ITRM920099A0 (it) 1992-02-17

Similar Documents

Publication Publication Date Title
Seligmann et al. Alpha-chain disease: a new immunoglobulin abnormality
Medicus et al. Role of human factor I and C3b receptor in the cleavage of surface‐bound C3bi molecules
Andersson et al. Activated human T lymphocytes display new surface glycoproteins.
IL89865A0 (en) Anti-t-cell receptor determinants in autoimmune disease treatment
IL86809A (en) Second generation monoclonal antibodies with binding specificity to tag-72, method for detecting human carcinomas utilizing the same, and pharmaceutical compositions containing the same
ZA956254B (en) Peptides
NO900155L (no) Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
Lecomte-Raclet et al. New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
IT1254309B (it) Sequenze genetiche per l'antigene 90k associato a tumori.
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
AU5926496A (en) Peptide radiopharmaceutical applications
Carter et al. Isolation and partial characterization of “galactoprotein a”(LETS) and “galactoprotein b” from hamster embryo fibroblasts
Hohenwarter et al. Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
IT1264490B (it) Antigene 90k associato a tumori.
EP0675728A4 (en) MEANS AND METHODS FOR IMPROVING KERATINOYCTE ADHESION TO THE SKIN.
KR100425627B1 (ko) 포유동물의간으로부터추출된단백질및종양치료와관련한그이용방법
NO20026147D0 (no) Trombomodulinanaloger for marmasöytisk anvendelse
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
JPH0784481B1 (it)
Greiner et al. Differential responsiveness of cloned mammary carcinoma cell populations to the human recombinant leukocyte interferon enhancement of tumor antigen expression
Srebreva et al. Specificity studies on anti‐histone H1 antibodies obtained by different immunization methods
Jaffe et al. Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line
MX9805299A (es) Novedosos polinucleotidos panc1a y panc1b asociados con cancer pancreatico.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960412